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Background: Thiazolidinediones are oral diabetes medications that selectively activate peroxisome proliferator-
activated receptor gamma and have potent anti-inflammatory properties. While a few studies have found
improvements in pulmonary function with exposure to thiazolidinediones, there are no studies of their impact
on asthma exacerbations. Our objective was to assess whether exposure to thiazolidinediones was associated
with a decreased risk of asthma exacerbation.
Methods: We performed a cohort study of diabetic Veterans who had a diagnosis of asthma and were taking oral
diabetes medications during the period of 10/1/2005 – 9/30/2006. The risk of asthma exacerbations and oral steroid
use during 10/1/2006 – 9/30/2007 was compared between patients who were prescribed thiazolidinediones and
patients who were on alternative oral diabetes medications. Multivariable logistic regression and negative binomial
regression analyses were used to characterize this risk. A sensitivity analysis was performed, restricting our evaluation
to patients who were adherent to diabetes therapy.
Results: We identified 2,178 patients who were on thiazolidinediones and 10,700 who were not. Exposure to
thiazolidinediones was associated with significant reductions in the risk of asthma exacerbation (OR = 0.79, 95% CI,
0.62 – 0.99) and oral steroid prescription (OR = 0.73, 95% CI 0.63 – 0.84). Among patients who were adherent to
diabetes medications, there were more substantial reductions in the risks for asthma exacerbation (OR = 0.64, 95% CI
0.47 – 0.85) and oral steroid prescription (OR = 0.68, 95% CI 0.57 – 0.81).
Conclusions: Thiazolidinediones may provide a novel anti-inflammatory approach to asthma management by
preventing exacerbations and decreasing the use of oral steroids.
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Asthma is a major cause of morbidity in the Unites States,
affecting 22 million people and annual costs of $56 billion
[1]. Much of this cost is related to the burden of acute
exacerbations, which leads to approximately 1.8 million
emergency room visits and 497,000 hospitalizations each
year [2]. Prevention of asthma exacerbations typically* Correspondence: srinne@uw.edu
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unless otherwise stated.relies on the use of inhaled corticosteroids to reduce
chronic airway inflammation [3]. However, many patients
find inhalers difficult to use and non-adherence to inhaled
corticosteroids is common [4]. Furthermore, 5-10% of
patients with severe asthma receive sub-optimal control
even with proper use of inhaled corticosteroids [5]. There-
fore, a major focus of drug development is discovering
new ways to decrease airway inflammation and prevent
asthma exacerbations.
Thiazolidinediones (TZDs), such as pioglitazone and
rosiglitazone, are oral diabetes medications that have
also been shown to have potent anti-inflammatory proper-
ties [6]. These medications act as selective agonists to thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[7]. PPARγ regulates gene expression by forming a hetero-
dimer with the retinoid X receptor and binding DNA at the
promoter region of targeted genes [8]. PPARγ activation
inhibits inflammatory cytokine production and release [9].
Exposure to TZDs in animal models of asthma is associ-
ated with decreased airway inflammation and improved
physical condition [10-18]. In humans, few studies have
examined the effect of TZDs on asthma, and those that
have been performed have focused on improvements
in pulmonary function and airway hyperresponsiveness
[19-21]. There are no clinical studies on the impact of
TZDs on asthma exacerbations or oral steroid use.
Our primary objective was to examine how exposure
to TZDs is associated with asthma exacerbation among
diabetic patients. We also assessed the relationship between
TZD exposure and oral steroid prescriptions among this
patient population.Methods
Design
We performed a cohort study of US Veterans receiving
healthcare at Veterans Affairs (VA) medical facilities.
Information was collected from electronic medical re-
cords of all VA service users. Baseline characteristics
and TZD use were assessed during the 2006 fiscal year
(10/1/2005 – 9/30/2006), and outcomes were assessed
during the 2007 fiscal year (10/1/2006 – 9/30/2007). The
study was approved by the VA Puget Sound Institutional
Review Board (#01456).Study cohort
Study participants were identified by having two or more
ICD-9 diagnoses of diabetes and having received at least
two prescriptions for an oral antihyperglycemic medication
(TZDs, sulfonylurea, or metformin) during the baseline
year. Patients with co-existing asthma were identified
based on outpatient and inpatient criteria. Outpatient
criteria included having two or more outpatient visits
with an ICD-9 code for asthma or having one outpatient
visit with a diagnosis of asthma and a prescription for
albuterol. Inpatient criteria included having a discharge
diagnosis of asthma.
Exposure to TZD was defined as having filled a pre-
scription for TZDs on two or more occasions during the
baseline year. The majority of TZD patients in our study
were prescribed rosiglitazone (96%), which was on the
medication formulary at the VA during the study period;
only 4% of TZD patients were prescribed pioglitazone.
Patients who were exposed to TZDs could have also been
prescribed other oral diabetes medications. The reference
comparison was having filled a prescription for a non-TZD
oral antihyperglycemic medication (either sulfonylureaor metformin) on two or more occasions during the
baseline year. We chose to use a heterogeneous non-TZD
comparison group in order to emphasize the impact of
TZDs in asthma. We did perform additional analyses
comparing TZDs to metformin use and sulfonylurea
use separately and found similar results. Patients were
excluded from the study if they filled only one prescription
for TZDs during the baseline year.
Covariates included baseline patient characteristics, co-
morbidities, and current respiratory medication use. The
severity of diabetes was measured by the Diabetes Severity
Index score [22]. Overall patient health care burden was
further evaluated using Diagnostic Cost Group scores
[23]. Information on the number of asthma exacerbations
and prescriptions for respiratory medications in the base-
line was also recorded.
Study outcomes
The primary outcome was asthma exacerbation, including
inpatient or outpatient exacerbations during the follow-up
year. Inpatient asthma exacerbations were defined by a
primary ICD-9 discharge diagnosis of asthma or having a
primary ICD-9 discharge diagnosis of acute respiratory
failure and a secondary diagnosis of asthma. Outpatient
asthma exacerbations included a primary clinic diagnosis
of asthma accompanied by a prescription for oral steroids
within 2 days of the visit. Due to the low prevalence of
asthma exacerbations, inpatient and outpatient exacerba-
tions were grouped together for the analysis. A secondary
outcome was any oral steroid prescription. All patients
were monitored for outcomes during the entire follow
up year (10/1/2006 – 9/30/2007). We separated measure-
ments of the exposure (during the baseline year) and the
outcome (during the follow-up year) in order to limit the
potential for immortal time bias [24].
Statistical analysis
All statistical analyses were performed using Stata 11.2
[25]. Logistic regression was used to analyze the odds of
any asthma exacerbation and any prescription of an oral
steroid prescription during the follow-up year. Results
were reported using odds ratios (OR) and 95% confidence
intervals (CI). Negative binomial regression was used
to evaluate the association of TZDs with the expected
number of events. Results were reported as incidence
rate ratios (IRR), which were derived by dividing the
expected number of events among the TZD group by
the expected number of events among the non-TZD
group. For example, an IRR of 0.6 indicates that the TZD
group has a 40% lower number of events than expected in
the non-TZD group.
A sensitivity analysis was performed on patients who
were most adherent to diabetes medications. Adherence
was based on medication possession ratios which were
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six months prior to the outcome period [26]. Patients
were only included in the sensitivity analysis if they had
a ReComp score of at least 0.8.Age (mean/SD) 64.0 (10.4) 64.8 (11.1) <0.01
Female (%) 6.9 7.6 0.28
Race
White (%) 59.9 64.5 <0.01
Nonwhite (%) 21.0 18.7 0.01
Race unknown (%) 19.1 16.8 0.01
VA Freecare (%) 59.0 57.1 0.12
Distance to VA (mean/SD) 24.8 (31.4) 24.7 (30.0) 0.93
Physician encounters (mean/SD) 7.0 (5.7) 6.6 (5.6) 0.01
Prior exacerbations (mean/SD) 0.8 (1.6) 0.9 (1.7) 0.04
Diabetes severity index (mean/SD) 1.5 (1.6) 1.2 (1.4) <0.01
Diagnostic cost group (mean/SD) 1.12 (0.7) 1.07 (0.7) 0.01
Comorbidities
Atrial fibrillation (%) 6.0 8.0 0.02
Congestive heart failure (%) 6.0 7.5 0.01
Coronary artery disease (%) 22.5 20.5 0.05
Drug or alcohol abuse (%) 7.5 11.0 <0.01
Depression (%) 15.3 14.6 0.37
Medications
Short acting β-agonist (mean/SD) 5.6 (6.5) 6.0 (6.6) 0.01
Inhaled corticosteroid (%) 47.0 51.7 <0.01
Leukotriene modifier (%) 28.5 25.9 0.01
Long acting β-agonist (%) 38.0 40.5 0.03Results
We identified 13,528 diabetic Veterans who had two or
more prescriptions for oral diabetic medications and had
been diagnosed with asthma (Figure 1). Of these, 2,178
patients had received two or more prescriptions for TZDs
during the baseline year, while 10,700 did not receive any
prescription for TZDs. Patient attrition was low in our
study with 94.7% of patients had at least one clinic visit
during the follow-up year (mean = 5.76 visits, SD = 5.73).
Censorship was not different between the two study
groups (5.7% of TZD patients 5.2% of non-TZD patients
were seen in the VA during the follow up year).
Patients in the TZD group were more likely to be
younger, nonwhite, and have more primary care visits
when compared with the non-TZD group (Table 1).
These patients also had more severe diabetes and had a
higher diagnostic cost group score. While patients in the
TZD group had a lower prevalence of atrial fibrillation,
heart failure, and substance abuse, they had a higher
prevalence of coronary artery disease. The TZD group
had fewer asthma exacerbations in the year prior to the
study and were prescribed fewer short-acting beta agonists,
fewer inhaled corticosteroids, and fewer long-acting beta
agonists. In contrast, they had more prescriptions for
leukotriene modifiers.Figure 1 Study selection.Asthma exacerbations
In the unadjusted analysis (Table 2), patients in the TZD
group were less likely to experience at least one exacerba-
tion (inpatient or outpatient) compared to those in the
non-TZD group (4.7% versus 5.9%, p = 0.03). There was
no significant difference in the total number of exacerba-
tions between the two groups (0.08 for the TZD group
versus 0.10 for the non-TZD group, p = 0.06).
After controlling for potential confounding factors
(Table 3), there was a significantly decreased risk for any
asthma exacerbations among patients in the TZD group
(adjusted OR of 0.79 (95% CI 0.62 – 0.99), indicatingTable 2 Asthma exacerbations and oral steroid
prescriptions among the TZD and non-TZD groups
Event TZD Non-TZD p-value
Patients with an exacerbation* (%) 4.7 5.9 0.03
# of exacerbations (mean/SD) 0.08 (0.41) 0.10 (0.54) 0.06
Patients with a steroid prescription (%) 15 · 1 19.4 <0.01
# of steroid prescriptions (mean/SD) 0.35 (1.32) 0.50 (1.66) <0.01
*Includes both inpatient and outpatient exacerbations.
Table 3 Association of TZDs with asthma exacerbations
and steroid prescriptions in multivariable models*
Event Any event† Number of events‡
OR 95% CI IRR 95% CI
Asthma exacerbation 0.79 0.62 – 0.99 0.81 0.64 – 1.02
Steroid prescription 0.73 0.63 – 0.84 0.68 0.58 – 0.80
*Adjusted for age, gender, race, free care, distance to VA facility, number of
primary care encounters, Diagnostic Cost Group score, Diabetes Severity Index
score, prior year exacerbations, atrial fibrillation, heart failure, ischemic heart
disease, alcohol or drug abuse, and depression, respiratory medications.
†Logistic regression with outcome being presence of asthma exacerbation or
steroid prescription. Results are presented in odds ratios (OR) and 95%
confidence intervals (CI).
‡Negative binomial regression with outcome being number of asthma
exacerbations or number of steroid prescriptions. Results are presented in
incidence rate ratios (IRR) and 95% confidence intervals.
Table 4 Sensitivity analysis with multivariable models*
to evaluate the association of TZDs with asthma
exacerbations and steroid prescriptions among patients
who were most adherent to oral diabetes therapy
(ReComp scores ≥ 0.8)
Event Risk of any event† Risk of multiple events‡
OR 95% CI IRR 95% CI
Asthma Exacerbation 0.64 0.47 – 0.85 0.65 0.48 – 0.88
Steroid prescription 0.68 0.57 – 0.81 0.65 0.54 – 0.79
*Adjusted for age, gender, race, free care, distance to VA facility, number of
primary care encounters, Diagnostic Cost Group score, Diabetes Severity Index
score, prior year exacerbations, atrial fibrillation, heart failure, ischemic heart
disease, alcohol or drug abuse, and depression, respiratory medications.
†Logistic regression with outcome being presence of asthma exacerbation or
steroid prescription. Results are presented in odds ratios (OR) and 95%
confidence intervals (CI).
‡Negative binomial regression with outcome being number of asthma
exacerbations or number of steroid prescriptions. Results are presented in
incidence rate ratios (IRR) and 95% confidence intervals.
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experiencing at least one asthma exacerbation in the
study period. There was no significant difference in the
expected incidence of exacerbations in the TZD group
(adjusted IRR of 0.81, 95% CI 0.64 – 1.02).
Oral steroid prescriptions
In the unadjusted analysis, the TZD group was less likely to
receive a prescription for oral steroids than the non-TZD
group (15.1% versus 19.4%, p < 0.01). On average, the TZD
group also received fewer prescriptions for steroids com-
pared to the non-TZD group (0.35 versus 0.50, p < 0.01).
After controlling for potential confounding, there was
a significantly decreased risk for at least one oral steroid
prescription among the TZD group (adjusted OR = 0.73,
95% CI 0.63 – 0.84). Patients exposed to TZDs also had a
significantly lower expected number of steroid prescriptions
(adjusted IRR = 0.68, 95% CI 0.58 – 0.80). This indicates
that the expected number of oral steroid prescriptions in
the TZD group is 32% lower than the expected number
for the non-TZD group.
Sensitivity analysis
Restricting our analysis only to patients who were adher-
ent to oral diabetes medications (with ReComp scores of
at least 0.8) yielded more pronounced results (Table 4).
There were 1,474 patients who were adherent to therapy
in the TZD group and 8,208 patients who were adherent
to therapy in the non-TZD group. In this analysis,
patients in the TZD group had a significantly lower risk
of an asthma exacerbation (adjusted OR = 0.64, 95% CI
0.47 – 0.85). The expected incidence of asthma exacer-
bations was also significantly lower in the TZD group
(adjusted IRR = 0.65, 95% CI 0.48 – 0.88). Patients in the
TZD group had a lower risk of having been prescribed
any oral steroid (adjusted OR = 0.68, 95% CI 0.57 – 0.81).
Similarly, these patients had a lower expected number
of steroid prescriptions (adjusted IRR = 0.65, 95% CI
0.54 – 0.79).Discussion
This is the first clinical study examining the association of
TZDs with asthma exacerbations and steroid prescrip-
tions. Consistent with prior studies showing that TZDs
have potent anti-inflammatory effects, we found signifi-
cant reductions in asthma exacerbations and oral steroid
prescriptions among patients who were exposed to TZDs.
This study provides new evidence that TZDs may have a
role in the future treatment of asthma among patients
with diabetes.
Prevention of asthma exacerbations has been a corner-
stone of guidelines on asthma management [3]. First line
therapies target decreasing airway inflammation through
the use of inhaled corticosteroids, which reduce the risk of
asthma exacerbation by more than 50% [27]. However, in-
haled corticosteroids are not always effective, and despite
having less systemic distribution than oral steroids, they
are still associated with multiple adverse effects [28].
While many patients in our study were already on inhaled
corticosteroids, exposure to TZDs was associated with a
further reduction in the risk for exacerbation.
Our findings demonstrating the beneficial effect of TZDs
on asthma have a plausible biological mechanism. TZDs
are agonists to PPARγ and are involved in a variety of
biological functions, including the inflammatory response
[29]. Activation of PPARγ inhibits the production and
release of cytokines and cell survival factors involved in
inflammation [30]. A study on human airway smooth
muscle cells found PPARγ agonists were more effective at
inhibiting inflammatory cytokine release than corticoste-
roids [31]. Animal models of asthma that are exposed to
TZDs have consistently demonstrated reduced airway
inflammation, mucus production, and airway hyperre-
sponsiveness [12-15]. A study of the effect of ciglitazone
on a murine model of asthma further demonstrated inhib-
ition of airway smooth muscle remodeling [14]. This body
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management.
Ours is the first large study looking at clinical out-
comes among patients with asthma, and our findings are
consistent with prior studies that showed improvements
in pulmonary function and bronchoconstriction among
asthmatic patients. Case reports of two diabetic patients
with asthma found improvement in respiratory symptoms
after initiation of pioglitazone [32]. In one of the patients,
spirometry was measured before and after starting TZDs,
and there was a significant improvement in both FVC
and FEV1. A placebo controlled randomized study of 32
patients also found a modest decrease in late phase
asthma reactivity to allergen challenge after four weeks
of treatment with rosiglitazone [19]. A separate study of
16 asthmatic patients found a similar decrease in airway
bronchoconstriction with methacholine challenge after
12 weeks of treatment with rosiglitazone [20]. Comparing
rosiglitazone with inhaled corticosteroid treatment, a
randomized trial of 46 patients with asthma showed im-
provement in FEV1 and FEF25–75% among patients treated
with rosiglitazone [21]. Our findings, using a much larger
sample of patients, are consistent with these studies and
demonstrate a positive impact of TZDs on asthmatic
patients.
While there may be a beneficial effect of TZDs in
asthma, it is also important to note TZDs have been
associated with multiple adverse effects, including weight
gain and heart failure, bladder cancer (in the case of
pioglitzone) and possible cardiovascular effects (in the
case of rosiglitazone) [33-35]. These adverse effects would
have to be weighed against any potential gain in asthma
management.
Limitations of this study include the non-randomized
study design. Though it would also be desirable to perform
a new-user study design in order to overcome biases with
prevalent-user studies, we did not have a large enough
sample size to evaluate new users of TZDs [36]. Fur-
thermore, because these are observational analyses, we
cannot infer causality in the association between TZDs
and decreased asthma exacerbations, though this does
add evidence to support their relationship. We attempted
to control for a broad range of potential confounding
factors, though unmeasured variables could have impacted
the outcome. Notably, we did not have data on tobacco
use or obesity, both of which are associated with asthma
development and asthma exacerbations [37,38]. We also
did not have information on spirometry or bronchopro-
vocation testing and could not adjust for the severity of
asthma based on these measures. Prescriptions for respira-
tory medications and prior asthma exacerbations may be a
marker of asthma severity and we included these variables
in our multivariable analyses, though prescriptions for
asthma medications is not a perfect proxy for severity [39].Our study population comprised mostly elderly, male
veterans, which may limit the generalizability of these
findings. Incidence of asthma exacerbations in our study
was low. This may be partly due to the population that
we studied, as the risk of asthma exacerbation decreases
with increasing age and with male gender [40]. In addition,
our definition of exacerbations may not have adequately
captured all patients experiencing an acute asthma attack.
We broadened our analysis to assess the impact of TZDs
on the risk for any oral steroid prescription and found simi-
lar results, though we could not ascertain the indication for
these prescriptions. Despite these limitations, we were able
to study a large cohort of asthmatic patients who were
taking TZDs and control for a wide variety of potential
confounding factors.
Conclusion
Our findings suggest that TZDs could provide a novel
approach for the prevention of asthma exacerbations
among patients with diabetes. While there have been
clinical studies on the association of TZDs with pulmon-
ary function and allergen challenge, randomized trials are
needed to study the role of TZDs in preventing asthma
exacerbations. This may provide an innovative develop-
ment in asthma management and help alleviate a growing
healthcare burden.
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